Publication Series
In this section you will find Publication Series market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
-
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 228 companies plus partners who are today developing 321 Alpha6Beta4 integrin pathway targeting drugs in 1113 developmental projects in cancer across 131 different targets. In addition, there is 1 suspended drug and another 134 drugs where development has been ceased. Learn More -
Liver Cancer Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 157 companies plus partners who are today developing 188 drugs targeting liver cancer in development. across 154 different targets. In addition, there are 2 suspended drugs and another 49 drugs where development has been ceased. Learn More -
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2013
$685.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 57 companies plus partners who are today developing 56 IL-7 pathway targeting drugs in 238 developmental projects in cancer across 61 different targets. In addition, there is 1 suspended drug and another 19 drugs where development has been ceased. Learn More -
Cellular Therapy in Oncology Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 72 companies plus partners who are today developing 59 cellular therapy drugs in 127 developmental projects in cancer across 25 different targets. In addition, there are 5 suspended drugs and another 62 drugs where development has been ceased. Learn More -
TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 257 companies plus partners who are today developing 344 TGF-beta receptor pathway targeting drugs in 1128 developmental projects in cancer across 183 different targets. In addition, there are 2 suspended drugs and another 180 drugs where development has been ceased. Learn More -
Ovarian Cancer Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 220 companies plus partners who are today developing 306 drugs targeting ovarian cancer in development. across 224 different targets. In addition, there are 8 suspended drugs and another 84 drugs where development has been ceased. Learn More -
Analytical Tool - Colorectal Cancer
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013A unique tool for analyzing the vast amount of strategic possibilities that have emerged in colorectal R&D and business development. Learn More -
Analytical Tool - Angiogenesis in Oncology
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents. Learn More -
Hematological Cancers Drug Pipeline Update 2013
$2,750.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 393 companies plus partners who are today developing 631 hematological cancer drugs in 1265 developmental projects in cancer across 331 different targets. In addition, there are 10 suspended drugs and another 196 drugs where development has been ceased. Learn More -
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 109 companies plus partners who are today developing 134 IL-5 pathway targeting drugs in 514 developmental projects in cancer across 116 different targets. In addition, there is 1 suspended drug and another 48 drugs where development has been ceased. Learn More -
Cytokine Therapy in Oncology Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 82 companies plus partners who are today developing 105 cytokine drugs in 206 developmental projects in cancer across 20 different targets. In addition, there are 2 suspended drugs and another 7 drugs where development has been ceased. Learn More -
Biologicals in Oncology Drug Pipeline Update 2013
$3,425.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 860 companies plus partners who are today developing 1460 biological drugs in 3194 developmental projects in cancer across 576 different targets. In addition, there are 25 suspended drugs and another 868 drugs where development has been ceased. Learn More -
Bladder Cancer Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 98 companies plus partners who are today developing 111 drugs targeting bladder cancer in development. across 90 different targets. In addition, there are 3 suspended drugs and another 30 drugs where development has been ceased. Learn More -
Analytical Tool - Peptides in Oncology
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer peptide R&D and business development. Learn More -
IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 172 companies plus partners who are today developing 222 IL-3 pathway targeting drugs in 789 developmental projects in cancer across 129 different targets. In addition, there are 4 suspended drugs and another 82 drugs where development has been ceased. Learn More
Publication Series
In this section you will find Publication Series market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
-
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 228 companies plus partners who are today developing 321 Alpha6Beta4 integrin pathway targeting drugs in 1113 developmental projects in cancer across 131 different targets. In addition, there is 1 suspended drug and another 134 drugs where development has been ceased. Learn More -
Liver Cancer Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 157 companies plus partners who are today developing 188 drugs targeting liver cancer in development. across 154 different targets. In addition, there are 2 suspended drugs and another 49 drugs where development has been ceased. Learn More -
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2013
$685.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 57 companies plus partners who are today developing 56 IL-7 pathway targeting drugs in 238 developmental projects in cancer across 61 different targets. In addition, there is 1 suspended drug and another 19 drugs where development has been ceased. Learn More -
Cellular Therapy in Oncology Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 72 companies plus partners who are today developing 59 cellular therapy drugs in 127 developmental projects in cancer across 25 different targets. In addition, there are 5 suspended drugs and another 62 drugs where development has been ceased. Learn More -
TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 257 companies plus partners who are today developing 344 TGF-beta receptor pathway targeting drugs in 1128 developmental projects in cancer across 183 different targets. In addition, there are 2 suspended drugs and another 180 drugs where development has been ceased. Learn More -
Ovarian Cancer Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 220 companies plus partners who are today developing 306 drugs targeting ovarian cancer in development. across 224 different targets. In addition, there are 8 suspended drugs and another 84 drugs where development has been ceased. Learn More -
Analytical Tool - Colorectal Cancer
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013A unique tool for analyzing the vast amount of strategic possibilities that have emerged in colorectal R&D and business development. Learn More -
Analytical Tool - Angiogenesis in Oncology
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents. Learn More -
Hematological Cancers Drug Pipeline Update 2013
$2,750.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 393 companies plus partners who are today developing 631 hematological cancer drugs in 1265 developmental projects in cancer across 331 different targets. In addition, there are 10 suspended drugs and another 196 drugs where development has been ceased. Learn More -
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 109 companies plus partners who are today developing 134 IL-5 pathway targeting drugs in 514 developmental projects in cancer across 116 different targets. In addition, there is 1 suspended drug and another 48 drugs where development has been ceased. Learn More -
Cytokine Therapy in Oncology Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 82 companies plus partners who are today developing 105 cytokine drugs in 206 developmental projects in cancer across 20 different targets. In addition, there are 2 suspended drugs and another 7 drugs where development has been ceased. Learn More -
Biologicals in Oncology Drug Pipeline Update 2013
$3,425.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 860 companies plus partners who are today developing 1460 biological drugs in 3194 developmental projects in cancer across 576 different targets. In addition, there are 25 suspended drugs and another 868 drugs where development has been ceased. Learn More -
Bladder Cancer Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 98 companies plus partners who are today developing 111 drugs targeting bladder cancer in development. across 90 different targets. In addition, there are 3 suspended drugs and another 30 drugs where development has been ceased. Learn More -
Analytical Tool - Peptides in Oncology
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer peptide R&D and business development. Learn More -
IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 172 companies plus partners who are today developing 222 IL-3 pathway targeting drugs in 789 developmental projects in cancer across 129 different targets. In addition, there are 4 suspended drugs and another 82 drugs where development has been ceased. Learn More